Nexus Medical Partners

Zipit Wireless is a Greenville, SC-based company delivering cloud-based software and cellular services for Internet of Things products. The Company offers a subscription billing and activations platform that provides cellular activation, pricing subscription orders, accounting services, and business reports. Zipit Wireless markets its software and services worldwide.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

Sabal Medical is a healthcare platform that connects nurses and pharmacists together.

Zipit Wireless is a Greenville, SC-based company delivering cloud-based software and cellular services for Internet of Things products. The Company offers a subscription billing and activations platform that provides cellular activation, pricing subscription orders, accounting services, and business reports. Zipit Wireless markets its software and services worldwide.

Zipit Wireless is a Greenville, SC-based company delivering cloud-based software and cellular services for Internet of Things products. The Company offers a subscription billing and activations platform that provides cellular activation, pricing subscription orders, accounting services, and business reports. Zipit Wireless markets its software and services worldwide.

Sabal Medical is a healthcare platform that connects nurses and pharmacists together.

MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

Selah Technologies, LLC is an advanced materials manufacturing company developing and commercializing two proprietary nanotechnologies. Selah Dotsâ„¢ are patent-pending photoluminescent carbon-based nanoparticles. Selah Tubesâ„¢ are enriched single-walled nanotubes with precisely engineered electronic properties protected under US Patent No. 7,374,685. Our mission is to consistently deliver high quality nanomaterials and nano-enabled products to the global marketplace. Our growth strategy is to leverage relationships with market leading companies to establish mutually beneficial joint research and development agreements. Our strategy is founded in the conviction that early successes in our target markets will occur via exploitation of nanomaterials in established applications in which their incorporation is both useful and compelling, and addresses needs that nanotechnology can fulfill either immediately or in the very short term.

Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures LLC.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases — from inflammatory diseases to cancer — based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.

Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.

Lead poisoning threatens millions of people, yet is entirely preventable. Our mission is to help identify and protect those at risk. Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Headquartered outside Boston in Billerica, Massachusetts, Magellan is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure. Magellan Diagnostics has been a pioneer in the analysis of blood lead since the late 1960s, when the company (then called ESA, Inc.) was founded by four PhD graduates from the Massachusetts Institute of Technology (MIT). Applying a novel technique called Anodic Stripping Voltammetry (ASV), they designed and built a bench top analyzer for the measurement of lead in blood. The company then adapted this technology to create smaller, portable instruments that can be used outside of the traditional reference laboratory. This major achievement broadened the accessibility of lead testing by bringing it to the point of care.

Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases–including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.